Detection of annexin A autoantibodies in sera from colorectal cancer patients

Journal of Clinical Gastroenterology

Volumn 45, Issue 2, 2011, Pages 125-132

  Chen, Jinn Shiun ^a,b   Chou, Yeh Pin ^b,c   Chen, Kuei Tien ^c   Hung, Ray Ping ^c   Yu, Jau Song ^c   Chang, Yu Sun ^a   Chan, Err Cheng ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

annexin A; autoantibody response; Colorectal cancer; ELISA

Indexed keywords

AUTOANTIBODY; CARCINOEMBRYONIC ANTIGEN; LIPOCORTIN 4;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A4; ANNEXINS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 78951479531     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181e880ee     Document Type: Article

References (65)

1. Chen LT, Whang-Peng J. Current status of clinical studies for colorectal cancer in Taiwan. Clin Colorectal Cancer. 2004; 4:196-203.
2. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107: 1183-1188.
3. Liang JT, Cheng YM, Chang KJ, et al. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes B2 rectal cancer after curative resection. Hepatogastroenterology. 1999; 46:830-837.
4. Angelopoulou K, Diamandis EP, Sutherland DJ, et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994; 58:480-487.
5. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777-1788.
6. Yagihashi A, Asanuma K, Kobayashi D, et al. Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer. 2005;48:217-221.
7. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153:49-55.
8. Atalay C, Atalay G, Yilmaz KB, et al. The role of anti-CENPB and anti-SS-B antibodies in breast cancer. Neoplasma. 2005;52:32-35.
9. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001;108: 1411-1415.
10. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998;76:652-658.
11. Brass N, Heckel D, Sahin U, et al. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet. 1997;6:33-39.
12. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev. 1995;145:33-59.
13. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868-873.
14. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008;63:228-233.
15. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006;66:1181-1190.
16. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4: 1123-1133.
17. Duncan R, Carpenter B, Main LC, et al. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008;98:426-433.
18. Wozny W, Schroer K, Schwall GP, et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics. 2007;7:313-322.
19. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005; 6:449-461.
20. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331-371.
21. Kourie JI, Wood HB. Biophysical and molecular properties of annexin-formed channels. Prog Biophys Mol Biol. 2000;73: 91-134.
22. Rand JH. The annexinopathies: a new category of diseases. Biochim Biophys Acta. 2000;1498:169-173.
23. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics. 2003;3:45-55.
24. Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209:111-118.
25. Choi S, Kobayashi M, Wang J, et al. Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis. 2000;18:45-50.
26. Benz J, Hofmann A. Annexins: from structure to function. Biol Chem. 1997;378:177-183.
27. Smith PD, Moss SE. Structural evolution of the annexin supergene family. Trends Genet. 1994;10:241-246.
28. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997;70:46-51.
29. Broll R, Duchrow M, Oevermann E, et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis. 2001;16:22-27.
30. Tang R, Ko MC, Wang JY, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer. 2001;94:859-863.
31. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000;60: 1815-1817.
32. Reipert BM, Tanneberger S, Pannetta A, et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother. 2005;54:1038-1042.
33. Kocer B, McKolanis J, Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol. 2006;6:4.
34. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98:9824-9829.
35. Fernandez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res. 2004;64:5089-5096.
36. Masaki T, Tokuda M, Ohnishi M, et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology. 1996;24:72-81.
37. Reeves SA, Chavez-Kappel C, Davis R, et al. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 1992;52: 6871-6876.
38. Vishwanatha JK, Chiang Y, Kumble KD, et al. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis. 1993;14: 2575-2579.
39. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999; 340:994-1004.
40. Hoffmann P, Ji H, Moritz RL, et al. Continuous freeflow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215: a non twodimensional gel electrophoresis-based proteome analysis strategy. Proteomics. 2001;1:807-818.
41. Simpson RJ, Connolly LM, Eddes JS, et al. Proteomic analysis of the human colon carcinoma cell line (LIM 1215): development of a membrane protein database. Electrophoresis. 2000; 21:1707-1732.
42. Kraus M, Romisch J, Bastian B, et al. Detection of human anti-annexin autoantibodies by enzyme immunoassays. J Immunoassay. 1992;13:411-439.
43. Cole SP, Pinkoski MJ, Bhardwaj G, et al. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer. 1992;65:498-502.
44. Gillette JM, Chan DC, Nielsen-Preiss SM. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem. 2004;92:820-832.
45. Han EK, Tahir SK, Cherian SP, et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer. 2000;83:83-88.
46. Hu N, Flaig MJ, Su H, et al. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res. 2004;10:6013-6022.
47. Walker A, Whynes DK, Chamberlain JO, et al. The cost of screening for colorectal cancer. J Epidemiol Community Health. 1991;45:220-224.
48. Hardcastle JD, Balfour TW, Amar SS. Screening for symptomless colorectal cancer by testing for occult blood in general practice. Lancet. 1980;1:791-793.
49. Saito H, Soma Y, Koeda J, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer. 1995;61:465-469.
50. Wahrendorf J, Robra BP, Wiebelt H, et al. Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev. 1993;2:221-227.
51. Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249:87-96.
52. Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol. 2005;21:59-63.
53. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155-159.
54. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351: 2704-2714.
55. Zalcman G, Tredaniel J, Schlichtholz B, et al. Prognostic significance of serum p53 antibodies in patients with limitedstage small cell lung cancer. Int J Cancer. 2000;89:81-86.
56. Kressner U, Glimelius B, Bergstrom R, et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer. 1998;77:1848-1851.
57. Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst. 1997;89:381-385.
58. Chang SC, Lin JK, Lin TC, et al. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol. 2005;26:65-75.
59. Nozoe T, Yasuda M, Honda M, et al. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology. 2007;54: 1422-1425.
60. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1:701-702.
61. Ralhan R, Nath N, Agarwal S, et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res. 1998;4:2147-2152.
62. Hammel P, Boissier B, Chaumette MT, et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut. 1997;40:356-361.
63. Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002;8:156-164.
64. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477.
65. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467-1471.